• Eledon entered a strategic partnership with Natera to use Prospera as the exclusive dd-cfDNA monitoring assay in its planned Phase 3 kidney transplant trial.
• The Phase 3 study of tegoprubart is expected to start in late 2026.
• The trial targets about 600 kidney transplant recipients across more than 100 transplant centers globally.
• Prospera will be used for longitudinal surveillance to track allograft injury signals during the investigational immunosuppression regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.